Identification of antigenic differences between the phosphorylated and nonphosphorylated forms of the E7 protein of human papillomavirus type 16

Sun-Ho Kee, Yong O. Choi, Yong Sang Song, Hyo P. Lee, Woo Hyun Chang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To analyze the antigenic properties of the human papillomavirus type 16 E7 oncoprotein, two monoclonal antibodies, VD6 and IB10, that have different reactivities to the E7 protein were generated. While the VD6 antibody reacted strongly with E7 protein in CaSki cell extracts, the other antibody, IB10, showed much weaker reactivity with E7. This reactivity increased in a dose-dependent manner in the presence of the casein kinase II-specific inhibitor DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole). Antigenic site estimation and an in vitro phosphorylation assay, using bacterially expressed E7 protein, demonstrated that the weak reactivity of IB10 was related to the phosphorylation status of the E7 protein. Phosphorylation of E7 reduced considerably the reactivity of IB10 but did not affect the reactivity of VD6, which reacts with the N-terminal portion of E7. In immunoprecipitation (IP) assays, IB10 precipitated weakly the E7 protein from CaSki cell extracts. Together, these data suggest that unphosphorylated E7 protein shows distinct antigenic character compared to its phosphorylated form under denaturing conditions; however, under native conditions, the phosphorylated and nonphosphorylated E7 proteins have some antigenic cross-reactivity.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalJournal of Medical Virology
Volume54
Issue number2
DOIs
Publication statusPublished - 1998 Feb 1
Externally publishedYes

Fingerprint

Human papillomavirus 16
Proteins
Dichlororibofuranosylbenzimidazole
Phosphorylation
Cell Extracts
Casein Kinase II
Antibodies
Oncogene Proteins
Immunoprecipitation
Monoclonal Antibodies

Keywords

  • Antigenesity
  • E7
  • Human papillomavirus
  • Monoclonal antibody

ASJC Scopus subject areas

  • Virology

Cite this

Identification of antigenic differences between the phosphorylated and nonphosphorylated forms of the E7 protein of human papillomavirus type 16. / Kee, Sun-Ho; Choi, Yong O.; Song, Yong Sang; Lee, Hyo P.; Chang, Woo Hyun.

In: Journal of Medical Virology, Vol. 54, No. 2, 01.02.1998, p. 129-134.

Research output: Contribution to journalArticle

@article{7b78ae243ac74966ac8444c8098722b9,
title = "Identification of antigenic differences between the phosphorylated and nonphosphorylated forms of the E7 protein of human papillomavirus type 16",
abstract = "To analyze the antigenic properties of the human papillomavirus type 16 E7 oncoprotein, two monoclonal antibodies, VD6 and IB10, that have different reactivities to the E7 protein were generated. While the VD6 antibody reacted strongly with E7 protein in CaSki cell extracts, the other antibody, IB10, showed much weaker reactivity with E7. This reactivity increased in a dose-dependent manner in the presence of the casein kinase II-specific inhibitor DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole). Antigenic site estimation and an in vitro phosphorylation assay, using bacterially expressed E7 protein, demonstrated that the weak reactivity of IB10 was related to the phosphorylation status of the E7 protein. Phosphorylation of E7 reduced considerably the reactivity of IB10 but did not affect the reactivity of VD6, which reacts with the N-terminal portion of E7. In immunoprecipitation (IP) assays, IB10 precipitated weakly the E7 protein from CaSki cell extracts. Together, these data suggest that unphosphorylated E7 protein shows distinct antigenic character compared to its phosphorylated form under denaturing conditions; however, under native conditions, the phosphorylated and nonphosphorylated E7 proteins have some antigenic cross-reactivity.",
keywords = "Antigenesity, E7, Human papillomavirus, Monoclonal antibody",
author = "Sun-Ho Kee and Choi, {Yong O.} and Song, {Yong Sang} and Lee, {Hyo P.} and Chang, {Woo Hyun}",
year = "1998",
month = "2",
day = "1",
doi = "10.1002/(SICI)1096-9071(199802)54:2<129::AID-JMV10>3.0.CO;2-E",
language = "English",
volume = "54",
pages = "129--134",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Identification of antigenic differences between the phosphorylated and nonphosphorylated forms of the E7 protein of human papillomavirus type 16

AU - Kee, Sun-Ho

AU - Choi, Yong O.

AU - Song, Yong Sang

AU - Lee, Hyo P.

AU - Chang, Woo Hyun

PY - 1998/2/1

Y1 - 1998/2/1

N2 - To analyze the antigenic properties of the human papillomavirus type 16 E7 oncoprotein, two monoclonal antibodies, VD6 and IB10, that have different reactivities to the E7 protein were generated. While the VD6 antibody reacted strongly with E7 protein in CaSki cell extracts, the other antibody, IB10, showed much weaker reactivity with E7. This reactivity increased in a dose-dependent manner in the presence of the casein kinase II-specific inhibitor DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole). Antigenic site estimation and an in vitro phosphorylation assay, using bacterially expressed E7 protein, demonstrated that the weak reactivity of IB10 was related to the phosphorylation status of the E7 protein. Phosphorylation of E7 reduced considerably the reactivity of IB10 but did not affect the reactivity of VD6, which reacts with the N-terminal portion of E7. In immunoprecipitation (IP) assays, IB10 precipitated weakly the E7 protein from CaSki cell extracts. Together, these data suggest that unphosphorylated E7 protein shows distinct antigenic character compared to its phosphorylated form under denaturing conditions; however, under native conditions, the phosphorylated and nonphosphorylated E7 proteins have some antigenic cross-reactivity.

AB - To analyze the antigenic properties of the human papillomavirus type 16 E7 oncoprotein, two monoclonal antibodies, VD6 and IB10, that have different reactivities to the E7 protein were generated. While the VD6 antibody reacted strongly with E7 protein in CaSki cell extracts, the other antibody, IB10, showed much weaker reactivity with E7. This reactivity increased in a dose-dependent manner in the presence of the casein kinase II-specific inhibitor DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole). Antigenic site estimation and an in vitro phosphorylation assay, using bacterially expressed E7 protein, demonstrated that the weak reactivity of IB10 was related to the phosphorylation status of the E7 protein. Phosphorylation of E7 reduced considerably the reactivity of IB10 but did not affect the reactivity of VD6, which reacts with the N-terminal portion of E7. In immunoprecipitation (IP) assays, IB10 precipitated weakly the E7 protein from CaSki cell extracts. Together, these data suggest that unphosphorylated E7 protein shows distinct antigenic character compared to its phosphorylated form under denaturing conditions; however, under native conditions, the phosphorylated and nonphosphorylated E7 proteins have some antigenic cross-reactivity.

KW - Antigenesity

KW - E7

KW - Human papillomavirus

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=0031891189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031891189&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9071(199802)54:2<129::AID-JMV10>3.0.CO;2-E

DO - 10.1002/(SICI)1096-9071(199802)54:2<129::AID-JMV10>3.0.CO;2-E

M3 - Article

C2 - 9496371

AN - SCOPUS:0031891189

VL - 54

SP - 129

EP - 134

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 2

ER -